"poor immunity" is a correct and usable phrase in written English.
It can be used to describe someone's weakened or compromised ability to fight off diseases or infections. It can also refer to a person's overall weak immune system. Example: "Due to his poor immunity, the patient was more susceptible to catching the flu."
Clues to look out for: Loss of feeling in the arms and legs, muscle weakness, vision problems, poor immunity.
Chantal Chaervey from Woodbridge in Suffolk has watched her 12-year-old son Harry, who has severe brain damage and poor immunity, catch 13 lung infections over the past year.
However, poor immunity results in viral persistence, chronic inflammation and finally liver cirrhosis and carcinoma.
For dealing with large static error due to poor immunity of the traditional fuzzy control, a novel interval type-2 fuzzy control system is proposed.
Sepsis is a potential complication of pneumonia but occurs usually in people with poor immunity or hyposplenism.
It could be speculated in this context that UPF factors may be specific markers of poor immunity in MSI primary CRCs.
In otherwise non-immune suppressed patients, genetic factors leading to poor cellular immunity and a marked trend to immune tolerance are statistically associated with the severity of AE, which includes metastasis formation [ 27, 28], e.g. HLA B8, DR3, DQ2 haplotype; however, this 'at risk' haplotype was not present in our patient which actually was HLA A11, A10; B41, B41; DR13 DQ33; DQ3, DQ3.
The poor antitumor immunity and the escape to the innate and adaptive immune responses are based on the downregulation of tumor cell Major Histocompatibility Complex (MHC) I and costimulatory molecules, alteration of DCs and macrophages function in tumor tissue, regulatory T cells induction, and tumor-mediated immune cell death [ 4].
Lymphopenia as a likely index of poor systemic immunity is an independent predictor of inferior outcome in patients with clear cell renal cell carcinoma (RCC).
It has been proved that inhibition of NK function contributes to poor tumor immunity [ 30, 31].
For example, intramuscular injection, or other forms of systemic delivery, provides poor mucosal immunity, while mucosal vaccination generates strong, albeit region-specific, mucosal protection.
